Unicycive Therapeutics (UNCY): Vivo Opportunity reports 9.99% beneficial ownership stake

Unicycive Therapeutics, Inc. disclosed in an amended Schedule 13G that Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC report beneficial ownership of 4,856,259 shares, or 9.99%, based on 27,855,257 shares outstanding as of Aug. 12, 2026. The stake includes 550,000 common shares plus conversion of Series A-3/A-4/A-5 preferred underlying warrants exercisable within 60 days.

Original reporting
Published Aug 14, 2026, 8:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 16, 2026, 1:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$UNCY
Neutral
medium confidence
Mentioned
$UNCY
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$UNCYNeutralLow
01

Why it matters

The key tradable element is governance and control risk from a holder at 9.99% with sole voting and dispositive power, plus conversion-linked exposure within 60 days.

02

Market read

This is a regulatory ownership update that can matter for control dynamics, but it does not include new corporate actions, clinical, or financing terms.

03

What to watch

The 9.99% conversion cap via blocking provisions could limit actual voting dilution dynamics, reducing immediate control impact versus the headline percentage.

Relevance 4/10Novelty 4/10Timing: ownership filing dated event 06/30/2026, published 2026-08-14

Background

The text summarizes an amended SEC Schedule 13G reporting beneficial ownership by Vivo Opportunity entities in Unicycive Therapeutics.

Company-level read

Ticker impact

$UNCYNeutralMedium confidence
Context

Unicycive Therapeutics discloses Vivo Opportunity’s amended Schedule 13G showing 9.99% beneficial ownership, including conversion-linked preferred warrants.

Expected impact

Near-term price reaction is likely limited unless follow-on activism, board changes, or financing terms are disclosed; watch for further 13D/13G amendments.

Evidence & confidence

The article is a regulatory ownership disclosure (Schedule 13G) with detailed share and conversion mechanics, but it does not state new activism, deal terms, or operational catalysts.

Market effects

For small-cap biotech, large near-threshold ownership stakes can signal potential governance pressure, but this filing alone does not change sector fundamentals.

None indicated.

None indicated.

Counterpoint

The stake may be passive and already contemplated; without a shift to Schedule 13D or explicit activism, the market may discount the signal.

Key entities

  • Unicycive Therapeutics, Inc.

    Subject of the Schedule 13G ownership disclosure, with shares outstanding and conversion-linked warrant mechanics described.

  • Vivo Opportunity Fund Holdings, L.P.

    Reporting person holding beneficial ownership of 4,856,259 shares, including common and conversion-eligible preferred warrant tranches.

  • Vivo Opportunity, LLC

    General partner listed as part of the reporting structure for the beneficial ownership position.

Related articles

MedAI 8/10

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA

Unicycive Therapeutics announced the FDA accepted its resubmitted NDA for Oxylanthanum Carbonate (OLC), setting a PDUFA target action date of March 25, 2027. The resubmission addresses manufacturing deficiencies cited in a prior CRL. OLC is an investigational phosphate binder for CKD patients on dialysis, with potential market advantages due to its formulation.

$UNCYMed

FDA accepts Unicycive resubmission for kidney drug application

Unicycive Therapeutics (UNCY) announced the FDA accepted its resubmitted New Drug Application for oxylanthanum carbonate, a treatment for hyperphosphatemia in chronic kidney disease patients. The FDA set a target action date of March 25, 2027. The resubmission includes new manufacturing data from a different vendor, following a Complete Response Letter in June 2026. The company hopes for potential approval and does not know if the FDA will conduct a pre-approval inspection.

$UNCYMedAI 8/10

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027

Unicycive Therapeutics (Nasdaq: UNCY) announced FDA acceptance of its resubmitted NDA for oxylanthanum carbonate, a treatment for hyperphosphatemia in chronic kidney disease patients. The FDA set a PDUFA date of March 25, 2027. The resubmission includes new manufacturing data. The company hopes for potential approval, pending FDA review and possible inspections.

$UNCYHighAI 8/10

Why is Unicycive Therapeutics stock rallying today?

Unicycive Therapeutics (UNCY) stock rose 3.5% after the FDA accepted its resubmission for oxylanthanum carbonate, a treatment for chronic kidney disease. The FDA set a March 2027 target action date. The resubmission includes new manufacturing data addressing prior deficiencies. The broader market also gained, supporting small-cap biotech stocks. The company faces ongoing legal action, capping gains.